Gap Inc vs Nuwellis Inc — how do they compare? Gap Inc trades at $20.66 (market cap $7.30B), while Nuwellis Inc trades at $2.96 (market cap $1.10M). The key difference: Gap Inc is far larger — about 6636.4× Nuwellis Inc's market cap, and Gap Inc pays a 3.45% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| GAP | NUWE | |
|---|---|---|
Market Cap | $7.30B | $1.10M |
Sector | Consumer Cyclical | Technology |
52-Week High | $29.13 | $558.26 |
52-Week Low | $18.35 | $2.80 |
Enterprise Value | $10.38B | -$709.83K |
Dividend Yield | 3.45% | — |
Signals from Pluang's Aura AI — not financial advice
Gap Inc. (GAP) trades at $20.13, up 1.67% today, with a bullish technical signal but mixed moving averages. The company shows strong profitability with a 6.25% net income margin and 27.58% ROE, supported by positive earnings beats in recent quarters. Revenue has stabilized around $15B, and cash flow from operations remains robust at $1.49B for 2025. Recent news highlights Gap's digital transformation and Athleta brand turnaround efforts, though legal investigations present headwinds.
The stock appears undervalued with a P/E of 8.05 and consensus price target of $27.00, implying 34% upside. Key opportunities include earnings growth and margin expansion, but risks involve competitive pressures and ongoing legal probes. Analyst sentiment is mixed with 39.58% buy ratings, suggesting cautious optimism for value-oriented investors.
Nuwellis (NUWE) trades at $3.22, up 15% in the last 24 hours, following a recent 35:1 reverse stock split executed on June 26, 2026. The medical technology company shows a mixed financial picture with a strong gross margin of 65.47% but significant net losses and negative profitability ratios. Recent news highlights expansion in pediatric care, new patent awards, and a $6 million public offering closed in June 2026 to fund operations. Technical indicators are predominantly bearish, with moving averages signaling strong selling pressure.
The outlook remains challenging due to persistent operating losses and negative cash flow, offset by strategic pediatric market expansion and new product innovation. Investment opportunity hinges on the company's ability to translate its high gross margin and recent capital raise into sustainable revenue growth and eventual profitability. Key risks include continued cash burn, execution of commercial strategy, and reliance on financing activities to fund operations.
Trailing returns across standard periods
Latest headlines on both assets
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →